enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Rating of “Hold” from Analysts

enGene Holdings Inc. (NASDAQ:ENGN) has earned a consensus rating of “Hold” from the fourteen ratings firms that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $11.0455.

Several brokerages recently issued reports on ENGN. Leerink Partners cut enGene from an “outperform” rating to a “market perform” rating and set a $2.00 price target on the stock. in a research report on Friday, May 8th. HC Wainwright lowered their target price on enGene from $6.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, June 16th. UBS Group cut their price target on enGene from $9.00 to $2.00 and set a “neutral” rating for the company in a research note on Thursday, May 14th. Raymond James Financial downgraded enGene from a “strong-buy” rating to an “outperform” rating and set a $4.00 price target for the company. in a report on Friday, May 8th. Finally, Piper Sandler cut shares of enGene from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $7.00 to $4.00 in a research note on Friday, May 8th.

enGene Trading Down 3.1%

Shares of enGene stock opened at $1.86 on Friday. enGene has a 1 year low of $1.40 and a 1 year high of $12.25. The company has a debt-to-equity ratio of 0.10, a quick ratio of 12.57 and a current ratio of 12.57. The company has a market capitalization of $124.60 million, a P/E ratio of -0.86 and a beta of -0.28. The company’s fifty day moving average is $2.29 and its two-hundred day moving average is $6.42.

enGene (NASDAQ:ENGN) last announced its earnings results on Monday, June 15th. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.91. During the same quarter in the previous year, the firm earned $0.51 earnings per share. Analysts forecast that enGene will post -1.84 earnings per share for the current year.

Institutional Investors Weigh In On enGene

Institutional investors have recently added to or reduced their stakes in the business. PFS Partners LLC lifted its holdings in shares of enGene by 22.2% in the 4th quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock valued at $99,000 after buying an additional 2,000 shares during the period. Millennium Management LLC grew its holdings in enGene by 57.3% during the third quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after acquiring an additional 7,472 shares during the period. Raymond James Financial Inc. grew its holdings in enGene by 383.6% during the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after acquiring an additional 7,932 shares during the period. Cresset Asset Management LLC purchased a new position in enGene in the second quarter worth $36,000. Finally, Paloma Partners Management Co purchased a new position in enGene in the second quarter worth $38,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.